9,10-Dimethyl-1,2-benzanthracene
"9,10-Dimethyl-1,2-benzanthracene" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
7,12-Dimethylbenzanthracene. Polycyclic aromatic hydrocarbon found in tobacco smoke that is a potent carcinogen.
| Descriptor ID |
D015127
|
| MeSH Number(s) |
D02.455.426.559.847.149.301 D04.615.149.301
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "9,10-Dimethyl-1,2-benzanthracene".
Below are MeSH descriptors whose meaning is more specific than "9,10-Dimethyl-1,2-benzanthracene".
This graph shows the total number of publications written about "9,10-Dimethyl-1,2-benzanthracene" by people in this website by year, and whether "9,10-Dimethyl-1,2-benzanthracene" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 2 | 2 |
| 2001 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "9,10-Dimethyl-1,2-benzanthracene" by people in Profiles.
-
Metz R, Smith C, DuHadaway JB, Chandler P, Baban B, Merlo LM, Pigott E, Keough MP, Rust S, Mellor AL, Mandik-Nayak L, Muller AJ, Prendergast GC. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. Int Immunol. 2014 Jul; 26(7):357-67.
-
Muller AJ, DuHadaway JB, Chang MY, Ramalingam A, Sutanto-Ward E, Boulden J, Soler AP, Mandik-Nayak L, Gilmour SK, Prendergast GC. Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother. 2010 Nov; 59(11):1655-63.
-
Chang MY, Boulden J, Sutanto-Ward E, Duhadaway JB, Soler AP, Muller AJ, Prendergast GC. Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res. 2007 Jan 01; 67(1):100-7.
-
Tomblyn S, Langenheim JF, Jacquemart IC, Holle E, Chen WY. The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice. Int J Oncol. 2005 Nov; 27(5):1381-9.
-
Stewart SL, Querec TD, Ochman AR, Gruver BN, Bao R, Babb JS, Wong TS, Koutroukides T, Pinnola AD, Klein-Szanto A, Hamilton TC, Patriotis C. Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia. Cancer Res. 2004 Nov 15; 64(22):8177-83.
-
Liu AX, Rane N, Liu JP, Prendergast GC. RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Mol Cell Biol. 2001 Oct; 21(20):6906-12.
-
Virmani J, Johnson EN, Klein-Szanto AJ, Funk CD. Role of 'platelet-type' 12-lipoxygenase in skin carcinogenesis. Cancer Lett. 2001 Jan 26; 162(2):161-5.
-
Sauter ER, Klein-Szanto AJ, Atillasoy E, Montone KT, Goodrow T, Binder RL, Seykora JT, Herlyn M. Ultraviolet B-induced squamous epithelial and melanocytic cell changes in a xenograft model of cancer development in human skin. Mol Carcinog. 1998 Nov; 23(3):168-74.
-
Zhang S, Klein-Szanto A. [p53 gene mutations in mouse skin tumors induced by DMBA-TPA-MNNG]. Zhonghua Bing Li Xue Za Zhi. 1998 Aug; 27(4):298-300.
-
Zhang SY, Liu SC, Goodrow T, Morris R, Klein-Szanto AJ. Increased expression of G1 cyclins and cyclin-dependent kinases during tumor progression of chemically induced mouse skin neoplasms. Mol Carcinog. 1997 Mar; 18(3):142-52.